Interleukin-10 mRNA expression in B-cell chronic lymphocytic leukaemia inversely correlates with progression of disease

被引：36

作者：

Sjoberg, J

AguilarSantelises, M

Sjogren, AM

Pisa, EK

Ljungdahl, A

Bjorkholm, M

Jondal, M

Mellstedt, H

Pisa, P

机构：

[1] KAROLINSKA HOSP, DEPT GEN ONCOL, S-10401 STOCKHOLM, SWEDEN

[2] KAROLINSKA INST, CTR MICROBIOL & TUMOR BIOL, STOCKHOLM, SWEDEN

[3] HUDDINGE HOSP, DEPT NEUROL, STOCKHOLM, SWEDEN

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 1996年 / 92卷 / 02期

关键词：

B-CLL; IL-10; progression; cytokine; PCR;

D O I：

10.1046/j.1365-2141.1996.00358.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Interleukin-10 (IL-10) has been shown in vitro to inhibit survival and spontaneous DNA synthesis in B-cell chronic lymphocytic leukaemia (B-CLL) cells by induction of programmed cell death. We have analysed the presence of mRNA transcripts for IL-10 in purified B-CLL cells from 35 patients by RT-PCR. Transcripts for IL-10 were detected in 11/20 patients with non-progressive disease. In cell preparations from patients with progressive B-CLL IL-10 mRNA were detected in only 2/15 samples (P less than or equal to 0.01). The Epstein-Barr virus status of the cells did not account for the difference in IL-10 mRNA expression observed between the two groups of patients. Thus, IL-IO mRNA expression in leukaemic cells from patients with B-CLL was strongly associated with non-progressive disease. This finding may support other observations suggesting that IL-10 might be a candidate for immune therapy of progressive B-CLL.

引用

页码：393 / 400

页数：8

共 43 条

[11]

Cheson B D, 1990, Oncology (Williston Park), V4, P71

[12]

CORTES JE, 1994, BLOOD, V84, pA160

[13] INTERLEUKIN-10 AND TRANSFORMING GROWTH-FACTOR-BETA COOPERATE TO INDUCE ANTI-CD40 ACTIVATED NAIVE HUMAN B-CELLS TO SECRETE IMMUNOGLOBULIN-A [J].